Thomas Raffay, MD
- Assistant Professor
Thomas Michael Raffay, MD, FAAP, is a neonatologist in the Division of Neonatology and Perinatal Medicine at University Hospitals Rainbow Babies & Children’s Hospital and Instructor, Pediatrics at Case Western Reserve University School of Medicine.
Dr. Raffay is board certified in pediatrics and neonatal-perinatal medicine and is certified in extra-corporeal membrane oxygenation (ECMO) and neonatal resuscitation. His special interest is in lung and respiratory problems in newborns. He joined the UH Rainbow Babies & Children’s Hospital staff in 2013.
Dr. Raffay earned his bachelor’s degree cum laude from Case Western Reserve University and his medical degree from The Ohio State University College of Medicine and Public Health, Columbus, Ohio. He completed his residency in pediatrics at Nationwide Children’s Hospital, Columbus, Ohio, and a William Randolph Hearst Neonatology Fellowship at UH Rainbow Babies & Children’s Hospital.
As a fellow, Dr. Raffay won several awards for basic research. His current research interest is lung development in the newborn infant. He presently is participating in a basic science research project in this field and has published abstracts and papers and presented lectures at local and national medical meetings about it.
He is a Fellow of the American Academy of Pediatrics.
Awards and Recognition
Fellow, American Academy of Pediatrics
William Randolph Hearst Neonatology Fellowship, UH Rainbow Babies & Children’s Hospital, 2011
Lung development in the newborn infant
- Neonatal/Perinatal Medicine - American Board of Pediatrics
- Pediatrics - American Board of Pediatrics
Fellowship | Neonatal-Perinatal Medicine
Neonatal-Perinatal Medicine - Uh Rainbow Babies And Children's Hospital (2010 - 2013)
Residency | Pediatrics
Pediatrics - Nationwide Children's Hospital (2007 - 2010)
The Ohio State University College Of Medicine (2003 - 2007)
Case Western Reserve University (2003)
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2016, Thomas Raffay did not disclose any Outside Relationships with Industry.